Your browser doesn't support javascript.
loading
Optimal drugs for second-line treatment of patients with small-cell lung cancer.
Rossi, Antonio; Sacco, Paola Claudia; Sgambato, Assunta; Casaluce, Francesca; Santabarbara, Giuseppe; Palazzolo, Giovanni; Maione, Paolo; Gridelli, Cesare.
Afiliação
  • Rossi A; a Division of Medical Oncology , 'S.G. Moscati' Hospital , Avellino , Italy.
  • Sacco PC; a Division of Medical Oncology , 'S.G. Moscati' Hospital , Avellino , Italy.
  • Sgambato A; b Department of Clinical and Experimental Medicine , Second University of Naples , Naples , Italy.
  • Casaluce F; b Department of Clinical and Experimental Medicine , Second University of Naples , Naples , Italy.
  • Santabarbara G; a Division of Medical Oncology , 'S.G. Moscati' Hospital , Avellino , Italy.
  • Palazzolo G; c Division of Medical Oncology , USLL5 , Cittadella (Pd) , Italy.
  • Maione P; a Division of Medical Oncology , 'S.G. Moscati' Hospital , Avellino , Italy.
  • Gridelli C; a Division of Medical Oncology , 'S.G. Moscati' Hospital , Avellino , Italy.
Expert Opin Pharmacother ; 17(7): 969-76, 2016.
Article em En | MEDLINE | ID: mdl-26878692
INTRODUCTION: Despite the high response rate to chemotherapy, there have been few advances in the treatment of small-cell lung cancer (SCLC) in the last decades. The state-of-the-art second-line therapy and future research developments in relapsed SCLC are reviewed. AREAS COVERED: There are no optimal drugs for second-line treatment of recurrent SCLC but only agents registered for this use. Topotecan remains the standard-of-care for the treatment of second-line platinum-sensitive SCLC patients worldwide, while amrubicin is another option, but registered only in Japan. To date, no targeted agents reporting interesting results in second-line SCLC treatment are available. The next-generation DNA sequencing should discover somatic gene alterations and their roles in SCLC to help in selecting patients who could benefit from a targeted agent. Two immunotherapeutics, ipilimumab and nivolumab, have shown promising preliminary results and are being investigated in ongoing trials. EXPERT OPINION: Second-line treatment is not an option for most SCLC patients. Given the evidence up to now, the potentials for immuno-oncology in SCLC are high. The hope is that these expectations are met, and that all drugs being developed will offer new and improved treatment options for SCLC patients.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Clinical_trials Limite: Humans Idioma: En Ano de publicação: 2016 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Clinical_trials Limite: Humans Idioma: En Ano de publicação: 2016 Tipo de documento: Article